King's College London, School of Cancer and Pharmaceutical Sciences, CAR Mechanics Lab, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.
King's College London, School of Cancer and Pharmaceutical Sciences, CAR Mechanics Lab, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK; Leucid Bio Ltd., Guy's Hospital, Great Maze Pond, London SE1 9RT, UK; Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK; Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex, BN21 2UD, UK.
Cancer Cell. 2021 Feb 8;39(2):138-140. doi: 10.1016/j.ccell.2020.12.019. Epub 2021 Jan 7.
CAR-engineered T cell immunotherapy has proven transformative in selected hematological malignancies. However, solid tumors largely remain impervious to these approaches. In addressing this challenge, Srivastava et al. in this issue demonstrate that oxaliplatin-based lymphodepleting chemotherapy promotes enhanced CAR T cell recruitment to lung tumors, boosting therapeutic impact in combination with anti-PD-L1.
嵌合抗原受体 T 细胞免疫疗法已被证明在某些血液恶性肿瘤中具有变革性。然而，实体瘤在很大程度上仍然对这些方法无动于衷。在解决这一挑战方面，Srivastava 等人在本期杂志中表明，基于奥沙利铂的淋巴清除化疗可促进 CAR T 细胞向肺部肿瘤募集，与抗 PD-L1 联合使用可增强治疗效果。
